Patents by Inventor Michael R. Kozlowski
Michael R. Kozlowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7071231Abstract: Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.Type: GrantFiled: September 6, 2002Date of Patent: July 4, 2006Assignee: Telik, Inc.Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V. V. S. V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum
-
Patent number: 7029695Abstract: Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.Type: GrantFiled: July 10, 2001Date of Patent: April 18, 2006Assignee: Telik, Inc.Inventors: Thomas Redelmeier, Lawrence M. Kauvar, Robert T. Lum, Matthew H. Lyttle, Robert W. Macsata, Steven R. Schow, Hugo O. Villar, Michael R. Kozlowski
-
Patent number: 6653321Abstract: Methods for treating conditions associated with hyperglycemia, especially Type II diabetes, with novel naphthylsulfonic acids and related compounds. These compounds, as single stereoisomers or mixtures of stereoisomers, or their pharmaceutically acceptable salts, are useful in methods of stimulating the kinase activity of the insulin receptor, enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.Type: GrantFiled: July 28, 2000Date of Patent: November 25, 2003Assignee: Telik, Inc.Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V. V. S. V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum, Louise Robinson, Jeong Weon Park
-
Publication number: 20030135063Abstract: Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.Type: ApplicationFiled: September 6, 2002Publication date: July 17, 2003Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V.V.S.V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum
-
Publication number: 20030100511Abstract: Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.Type: ApplicationFiled: July 10, 2001Publication date: May 29, 2003Inventors: Lawrence M. Kauvar, Robert T. Lum, Matthew H. Lyttle, Robert W. Macsata, Steven R. Schow, Hugo O. Villar, Michael R. Kozlowski
-
Patent number: 6506739Abstract: Bis-(N,N′-bis-(2-haloethyl)amino)phosphoramidates, pharmaceutical compositions containing them, methods of treatment using them, and processes for their preparation. The compounds possess anti-tumor activities or are capable of being modified to have anti-tumor activities; and this invention relates to the use of the compounds in methods for the treatment of tumors and, especially, for the treatment of cancer.Type: GrantFiled: May 1, 2001Date of Patent: January 14, 2003Assignee: Telik, Inc.Inventors: R. Jason Herr, Robert T. Lum, Steven R. Schow, Fanying Meng, Michael R. Kozlowski, Pavel Zhichkin
-
Patent number: 6458998Abstract: Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.Type: GrantFiled: May 25, 2000Date of Patent: October 1, 2002Assignee: Telik, Inc.Inventors: Wayne R. Spevak, Songyuan Shi, Prasad V. V. S. V. Manchem, Michael R. Kozlowski, Steven R. Schow, Robert T. Lum
-
Patent number: 6337338Abstract: Methods for treating diseases associated with the activity of the insulin growth factor-1 receptor (IGF-1R), such as cancer, are provided. Methods for inhibiting cell growth and proliferation, especially of tumor cells, and promoting apoptosis are also provided. Each of these methods employs the use of a heteroaryl-aryl urea compound as an antagonist for IGF-1R.Type: GrantFiled: December 15, 1999Date of Patent: January 8, 2002Assignee: Telik, Inc.Inventors: Michael R. Kozlowski, Robert T. Lum, Steven R. Schow, Hugo O. Villar, Micheal M. Wick
-
Patent number: 6274738Abstract: The invention provides DNA primase assays suitable for identifying DN primase modulating agents, methods of modulating DNA primase activity, compounds for modulating DNA primase activity, and compositions which modulate DNA primase.Type: GrantFiled: November 24, 1997Date of Patent: August 14, 2001Assignee: Geron CorporationInventors: Michael R. Kozlowski, Junko Aimi, Ryan Holcomb
-
Patent number: 6083713Abstract: The present invention relates to the cloning of .beta.APP-C100 receptor (C100-R), and genetically engineered host cells which express the C100-R. Such engineered cells may be used to evaluate and screen drugs and analogs of .beta.-APP involved in Alzheimer's Disease.Type: GrantFiled: November 15, 1995Date of Patent: July 4, 2000Assignees: Bristol-Myers Squibb Company, McLean Hospital CorporationInventors: Susan P. Manly, Michael R. Kozlowski, Rachael L. Neve
-
Patent number: 5854392Abstract: The present invention relates to the cloning of .beta.APP-C100 receptor (C100-R), and genetically engineered host cells which express the C100-R. Such engineered cells may be used to evaluate and screen drugs and analogs of .beta.-APP involved in Alzheimer's Disease.Type: GrantFiled: August 30, 1993Date of Patent: December 29, 1998Assignees: Bristol-Myers Squibb Company, McLean Hospital CorporationInventors: Susan P. Manly, Michael R. Kozlowski, Rachael L. Neve
-
Patent number: 5834193Abstract: Methods and compositions for the measurement of telomere length have application in medical diagnostic, prognostic, and therapeutic procedures. The methods for measuring telomere length include primer extension-based methods and probe-based methods. The primer extension methods involve elongation of telomeric, linker, and/or subtelomeric based primers under conditions such that the telomere serves as a template for primer extension and that the resultant primer extension products can be compared to standards of known length to provide a measure of telomere length. The probe based methods allow for telomere length measurements using DNA from lysed or whole cells and involve hybridizing an excess of probe to all telomeric repeat sequences in the telomere, measuring the amount of bound probe, and correlating the amount of bound probe measured with telomere length.Type: GrantFiled: June 7, 1996Date of Patent: November 10, 1998Assignee: Geron CorporationInventors: Michael R. Kozlowski, Karen R. Prowse, Sy-Shi Wang, Sharon Wong, Nam Woo Kim, Richard Allsopp
-
Patent number: 5760062Abstract: Methods and compositions for treating cancer and other diseases in which inhibition of telomerase activity can ameliorate disease symptoms or prevent or treat the disease relate to compounds that are derivatives of pyrido?b!thiophenes, pyrido?b!furans, pyridine ethers or pyridine thioethers. Such compounds are characterized by the following structure: ##STR1## X.sub.3 is oxygen or sulfur; and the double dashed lines between X.sub.4 and X.sub.5 indicate an optional double bond, which, when present, forms a fused, bicyclic pyrido?b!furan or pyrido?b!thiophene ring system, depending upon whether X.sub.3 is oxygen or sulfur, respectively. When the double bond is not present, the compound is a monocyclic pyridine ether or thioether, again depending upon whether X.sub.3 is oxygen or sulfur. X.sub.4 is --CH.sub.2 R.sub.21 or --CR.sub.21 --, where R.sub.Type: GrantFiled: April 18, 1995Date of Patent: June 2, 1998Assignee: Geron CorporationInventors: Federico C.A. Gaeta, Adam A. Galan, Michael R. Kozlowski, Karen R. Prowse, Elaine C. Stracker, Patricia A. Peterli-Roth
-
Patent number: 5741677Abstract: Methods are provided for the determination of telomere length. These methods can be used for diagnosis of cancer and the staging of cancer, and diagnosis of senecesence in cells. Also, the instant methods can be used to determine stages of diseases such as atherosclerosis or HIV infection, and can be used to diagnose infertility.Type: GrantFiled: June 7, 1995Date of Patent: April 21, 1998Assignee: Geron CorporationInventors: Michael R. Kozlowski, Karen R. Prowse, Sy-shi Wang, Sharon Wong, Nam Woo Kim, Richard Allsop
-
Patent number: 5332574Abstract: Disclosed are active compounds BU-4726G-A and BU-4726G-B which contain a quinone chromophore and hydroquinone chromophore, respectively. The compounds are produced by fermentation of Streptomyces exfoliatus AA4510. The compounds possess antimicrobial, and K.sub.ATP channel blocking activities.Type: GrantFiled: February 11, 1993Date of Patent: July 26, 1994Assignee: Bristol-Myers Squibb CompanyInventors: Koko Sugawara, Koji Tomita, Michael R. Kozlowski, Yosuke Sawada